Rybelsus tablets: Effect, application and FAQs

Who developed Rybelsus?

Manufacturer

Rybelsus is manufactured by Novo Nordisk, a global pharmaceutical company based in Denmark. Novo Nordisk has also developed other weight loss products such as Ozempic and Wegovy, which contain the same active ingredient as Rybelsus: Semaglutide.

Availability

Rybelsus has been on the market in the USA since 2019 and in the EU since 2020. It is only available on prescription, but is not currently marketed in Germany.

For which application is Rybelsus approved?

Rybelsus is approved for the treatment of adults with:

• Type 2 diabetes

Who is Rybelsus suitable for?

Rybelsus is suitable for adults with type 2 diabetes mellitus who need additional support with blood glucose control.

How does Rybelsus work?

Rybelsus contains semaglutide, which activates the GLP-1 receptors. This leads to increased insulin production, reduced glucagon release and slower gastric emptying. As a result, the blood sugar level remains more stable and the feeling of satiety lasts longer, which can contribute to weight loss. It also influences the hunger and satiety center in the brain.

Dosage and application

Rybelsus is available in doses of 3 mg, 7 mg and 14 mg. The starting dose is 3 mg once a day for the first four weeks. Thereafter, the dose can be increased to 7 mg, with a possible further increase to 14 mg.

The tablet is taken in the morning on an empty stomach with a maximum of 120 ml of water. Afterwards, you should not eat or drink for at least 30 minutes.

Where can I buy Rybelsus?

Rybelsus is not currently marketed in Germany.

Prices for Rybelsus

The cost of Rybelsus varies depending on the dosage and pack size.

What are the possible side effects?

Common side effects of Rybelsus are:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Loss of appetite

These symptoms usually occur at the start of treatment and subside over time. Rare but serious side effects can include pancreatitis or allergic reactions. If severe abdominal pain or allergic symptoms occur, a doctor should be consulted immediately.

Safety and approval Rybelsus

Rybelsus was approved by the European Commission on the recommendation of the European Medicines Agency (EMA). These approvals confirm that the use of this medicine is safe for adults with type 2 diabetes, overweight or obesity. Its efficacy has been proven in combination with a healthy and balanced diet.
Patients should inform their doctor about existing health problems and current medication before taking Rybelsus. Particular caution should be exercised in patients with a history of pancreatitis or severe gastrointestinal disorders. Use during pregnancy and breastfeeding is not recommended.

Interactions and contraindications

Patients should inform their doctor about existing health problems and current medication. If there is a history of pancreatitis or severe gastrointestinal disease, this should be discussed with a doctor before taking the product. Use during pregnancy and breastfeeding is not recommended.
Rybelsus can influence the effect of other blood sugar-lowering drugs such as insulin or sulphonylureas. It should not be taken by patients with:

• Type 1 diabetes
• Diabetic ketoacidosis
• severe gastrointestinal diseases

Differences between Rybelsus and other medications

Rybelsus vs. Ozempic

Rybelsus and Ozempic both contain semaglutide, but Rybelsus is taken as a tablet, while Ozempic is administered as an injection. Both drugs have a similar effect on blood glucose levels and body weight.

Rybelsus vs. Wegovy

Wegovy is specifically designed for weight loss, while Rybelsus is primarily intended for the treatment of type 2 diabetes. Both drugs contain semaglutide, but in different dosages.

How can I stop taking Rybelsus?

Discontinuation should take place in consultation with a doctor in order to avoid possible side effects.